[{"id":"8ca8a02d-8743-4c6b-a40b-ee548609ffbc","acronym":"OVSTAR","url":"https://clinicaltrials.gov/study/NCT04389229","created_at":"2021-01-18T21:11:12.940Z","updated_at":"2024-07-02T16:36:37.358Z","phase":"Phase 1/2","brief_title":"OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)","source_id_and_acronym":"NCT04389229 - OVSTAR","lead_sponsor":"Immetacyte Ltd","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • CoTIL-01 • UTIL-01 • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2020-12-15"}]